In the ever-changing world of pharma and biotech, uncertainty is the only certainty. Financial Planning & Analysis (FP&A) teams are increasingly turning to scenario planning to navigate risks and boost resilience. By modeling a range of potential outcomes, companies can better manage pipeline risks, regulatory complexities, market shifts, and macro-level challenges like economic instability. Scenario planning enables more strategic flexibility, optimizes resource allocation, and strengthens investor confidence. It’s not just about forecasting; it’s about preparing for multiple contingencies and turning uncertainty into a competitive advantage. Click the link below to learn more. https://lnkd.in/eVY9tUCX #Pharma #Biotech #FinancialPlanning #ScenarioPlanning #Strategy #FPA Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA
Spinnaker Life Sciences Strategy Consulting’s Post
More Relevant Posts
-
Commercial and IT leaders at emerging biopharma companies have to grapple with a lot of challenges leading up to launch: 💰Making strategic, “at-risk” investments 📊Navigating the complex data swamp ⚙️Deciding which tech to buy and which to build in-house 📈Preparing your infrastructure to scale Join our November 20 webinar for tried-and-tested guidance and case studies to navigate these decisions: https://hubs.ly/Q02Xm14h0 #EmergingBioPharma #PharmaAnalytics #DataAnalytics #BeghouConsulting
-
-
The biotech regulatory landscape is increasingly complex, with global variations creating challenges for innovation and compliance. Strategic planning, early regulatory engagement, and the use of data analytics are key approaches to help biotech companies navigate these hurdles. Read more about how to overcome these challenges and drive innovation with insights from Jeff Bartel, chairman and managing director of Hamptons Group. #BiotechRegulations #Innovation #Compliance #Regulation #BiotechStrategy
Biotech Regulatory Insights for Executives | Hamptons Group
shha.re
-
Scrip Asks...We Answer! When questioned about the funding environment outlook for 2024, Stefan Fischer explains “…We are seeing that big pharma is increasingly willing to make a bet on earlier-stage innovation, rather than just partner for late-stage assets.” In a continuingly challenging environment, “It is critical that companies spend wisely and drive programs forward in a focused way. At TVM, we take a capital-efficient approach for our early-stage, project-focused companies – providing sufficient funding to get to a key value inflection point – technical clinical proof of concept.” Read the full article, Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering by Eleanor Malone here: https://lnkd.in/eCKp9ZMA #vcfunding #mergersandacquisitions #lifescience
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
scrip.citeline.com
-
A fall in R&D and investment is reducing the pool of knowledge in the area of anti-microbial resistance. A lack of financial incentives has taken big pharma out of the fight says expert. Read more here: https://okt.to/zhd0lc
Expert warns of 'deepening crisis' in antimicrobial resistance research
-
Biotech Account Development Representative at PPD Clinical Research Services, Thermo Fisher Scientific
Check out this new white paper where our experts discuss the value that FSP engagements bring to biotech organizations.
FSP Model for Biotech Companies White Paper | PPD
https://www.ppd.com
-
US pharma and biotech leaders can stay ahead with smarter P&MA strategies. Explore how embracing business agility—the foundation of successful P&MA strategies—can drive value and better outcomes for your business! See Simon-Kucher’s proven agility framework in action. skp.link/jprp #BetterMarketAccess #BusinessAgility #PricingStrategy #PharmaInsights #SimonKucher
-
-
US pharma and biotech leaders can stay ahead with smarter P&MA strategies. Explore how embracing business agility—the foundation of successful P&MA strategies—can drive value and better outcomes for your business! See Simon-Kucher’s proven agility framework in action. skp.link/jprp #BetterMarketAccess #BusinessAgility #PricingStrategy #PharmaInsights #SimonKucher
-
-
Helping Pharma Managers Acquire Business-critical Competencies to Make Better Decisions
For my contacts who are involved in pharma and biotech valuations & deal making: 📋 I'm excited to share this handy checklist with critical factors that determine the unique risk profile of a company or product, which impacts the valuation. The list is created by CELforPharma faculty member Dr. Patrik Frei, who delivers our 1-day valuation course. 📖 Would you like a copy of this checklist? 💬 Just like this post and comment "YES," and I’ll send it your way! -------- ☝️ I am Inge 🔥 My mission: Helping Pharma managers acquire business-critical competencies to make better decisions Liked this post? Want to see more? 🔔 Ring the bell on my Profile to get notified 🔝 Connect with me #pharma #biotech #businessdevelopment #valuations Venture Valuation AG
-
-
US pharma and biotech leaders can stay ahead with smarter P&MA strategies. Explore how embracing business agility—the foundation of successful P&MA strategies—can drive value and better outcomes for your business! See Simon-Kucher’s proven agility framework in action. skp.link/jprp #BetterMarketAccess #BusinessAgility #PricingStrategy #PharmaInsights #SimonKucher
-
-
US pharma and biotech leaders can stay ahead with smarter P&MA strategies. Explore how embracing business agility—the foundation of successful P&MA strategies—can drive value and better outcomes for your business! See Simon-Kucher’s proven agility framework in action. skp.link/jprp #BetterMarketAccess #BusinessAgility #PricingStrategy #PharmaInsights #SimonKucher
-
